Kinetic and structural determinants for GABA-A receptor potentiation by neuroactive steroids.
Endogenous neurosteroids and synthetic neuroactive steroid analogs are among the most potent and efficacious potentiators of the mammalian GABA-A receptor. The compounds interact with one or more sites on the receptor leading to an increase in the channel open probability through a set of changes in the open and closed time distributions. The endogenous neurosteroid allopregnanolone potentiates the α1β2γ2L GABA-A receptor by enhancing the mean duration and prevalence of the longest-lived open time component and by reducing the prevalence of the longest-lived intracluster closed time component. Thus the channel mean open time is increased and the mean closed time duration is decreased, resulting in potentiation of channel function. Some of the other previously characterized neurosteroids and steroid analogs act through similar mechanisms while others affect a subset of these parameters. The steroids modulate the GABA-A receptor through interactions with the membrane-spanning region of the receptor. However, the number of binding sites that mediate the actions of steroids is unclear. We discuss data supporting the notions of a single site vs. multiple sites mediating the potentiating actions of steroids.
Akk
Gustav
G
Departments of Anesthesiology (GA, ASE, JHS), Washington University School of Medicine, St. Louis, MO, USA. akk@wustl.edu
Covey
Douglas F
DF
Evers
Alex S
AS
Mennerick
Steven
S
Zorumski
Charles F
CF
Steinbach
Joe Henry
JH
Eur J Neurosci. 2006 Oct;24(7):1955-66
17040476
Br J Pharmacol. 2009 Nov;158(5):1322-9
19702782
Science. 1986 May 23;232(4753):1004-7
2422758
J Neurosci. 2003 Nov 5;23(31):10013-20
14602815
Ann N Y Acad Sci. 2006 Nov;1088:139-52
17192562
J Physiol. 1997 Dec 1;505 ( Pt 2):283-97
9423172
Mol Neurobiol. 2008 Apr-Jun;37(2-3):116-25
18521763
Mol Pharmacol. 2008 Sep;74(3):614-27
18544665
Br J Pharmacol. 2008 Mar;153(5):1062-71
18204487
Br J Pharmacol. 2007 Jan;150(2):164-75
17160009
Mol Pharmacol. 2007 Feb;71(2):461-72
17105870
J Physiol. 2007 Nov 1;584(Pt 3):789-800
17761771
J Physiol. 2003 Feb 1;546(Pt 3):641-6
12562992
Trends Pharmacol Sci. 1999 Mar;20(3):107-12
10203866
Mol Pharmacol. 2006 Jun;69(6):2015-26
16554408
J Med Chem. 2008 Mar 13;51(5):1309-18
18275132
Recent Prog Horm Res. 1997;52:1-32
9238846
Channels (Austin). 2007 Jul-Aug;1(4):238-45
18708751
Brain Res Brain Res Rev. 2001 Nov;37(1-3):133-40
11744081
J Med Chem. 2007 Nov 29;50(24):6048-58
17963371
Endocrinology. 1999 Aug;140(8):3843-52
10433246
Proc Natl Acad Sci U S A. 2006 Sep 26;103(39):14602-7
16984997
J Neurosci. 2005 Dec 14;25(50):11605-13
16354918
Mol Pharmacol. 2009 Jun;75(6):1400-11
19289569
J Neurophysiol. 2009 Aug;102(2):1254-64
19553485
Front Neuroendocrinol. 2000 Jan;21(1):1-56
10662535
Neuropharmacology. 2009 Jan;56(1):149-54
18762201
Eur J Med Chem. 2008 Jan;43(1):107-13
17434649
Neuroreport. 1998 Feb 16;9(3):379-83
9512375
Mol Pharmacol. 2009 Apr;75(4):973-81
19176850
Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4711-6
16537405
Brain Res. 1993 Dec 3;629(2):283-92
8111631
Mol Pharmacol. 1991 Sep;40(3):333-6
1654510
J Physiol. 2004 Apr 15;556(Pt 2):387-99
14966300
J Mol Neurosci. 2006;28(1):33-51
16632874
J Physiol. 2001 Dec 15;537(Pt 3):715-33
11744750
Nature. 2006 Nov 23;444(7118):486-9
17108970
Pharm Res. 1990 Aug;7(8):869-73
2235884
J Physiol. 2004 Jul 1;558(Pt 1):59-74
15146041
Pharmacol Ther. 2007 Oct;116(1):1-6
17531324
Mol Pharmacol. 2007 Jun;71(6):1582-90
17341652